Management and Board

Cohava Gelber, Ph.D., MBA, Founder and Executive Chairperson, has vast experience in various executive positions in biotech and pharmaceutical companies (ImmuLogic Pharmaceutical Corp., Molecular Discoveries, MannKind Corp.). As vice president of R&D at Mannkind Corp. (MNKD), she was responsible for nonclinical development and clinical immune safety of drugs from pre-IND through phase III clinical trials. She has secured over $500M of federal funding and authored over 70 patents or patent applications. Dr. Gelber received her Ph.D. from the Weizmann Institute and MBA from Cornell University, as well as post-doctorate training at Stanford University.

Guy Yachin, Eng. MBA, President & CEO, entrepreneur and CEO of multiple biomedical companies. He has raised over $80M as CEO and Co-founder of Chiasma (CHAM) and MGVS. Mr. Yachin is an active board member of Orgenesis (ORGS), Enzymotec (ENZY), Remon Medical and others. He holds a BSc. and MBA from Technion Israeli Institute of Technology.

John H Abeles, MD, Board Member, is a venture investor, serial entrepreneur, and director of and advisor to medical science companies. He has medical and pharmacology training and a background in the pharma industry (Pfizer), Wall St (Kidder Peabody), and has played a key role in many early-stage medical companies.

Joel Kanter, Board Member, the President of Windy City, Inc., a privately held investment firm. Mr. Kanter has an extensive and distinguished career investing in and advising leading healthcare companies. In addition to his involvement with Serpin Pharma, Mr. Kanter was one of the founders of Prolor Biotech, Inc. (NYSE: PBTH) and the first investor and a Board Member of Medgenics, Inc. (NYSE: MEDG), as well as an investor and participant in a variety of other emerging healthcare entities.

Alexander Fleming, MD, Chair of SAB, Co-Founder of Kinexum LLC, a leading strategic consulting organization in the cardio-metabolic space. Dr. Fleming serves on several clinical advisory boards for major pharma and biotech companies. He was with the FDA for 12 years, where as head of the Metabolic Group, he played a key role in approving the first statin, growth hormones, and all diabetes drugs in the 1990s.

Antonio Abbate, MD, PhD, SAB Member, Vice-Chairman, Division of Cardiology, VCU. Dr. Abbate is the recipient of numerous awards and honors in both Italy and the United States and leads a multidisciplinary team conducting Clinical and Translational Research Program. He is the principal investigator or co-investigator on pilot clinical studies funded by the NIH, the American Heart Association, or industry. Dr. Abbate has authored 200 publications and over 300 oral presentations, and is the co-founder of COMET.

Antonio Gotto, MD, PhD, SAB Member, Dean Emeritus and Co-Chairman of the Board of Overseers of Weill Cornell Medical College in New York City, where he is also the Lewis Thomas University Professor. As a lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. An internationally renown speaker who has contributed more than 500 scholarly articles and books to the medical literature.

Jerome (“Jerry”) Zeldis, MD, PhD, SAB Member, has recently completed a distinguished 20-year career at Celgene during which he was instrumental in growing Celgene into one of the leading global biopharmaceutical companies. Most recently, Dr. Zeldis held the positions of Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene.

Jonathan Zelinman, MD, SAB Member, serves as Chief of Infectious Diseases Service at Johns Hopkins Bayview Medical Center, Inc. He is a professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Dr. Zenilman is an international authority on the clinical epidemiology and management of sexually transmitted diseases, HIV prevention, and infectious disease surveillance.